Internal Medicine, Medical Oncology · Huntsville, AL
NPI
1083693154
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3601 Cci Dr NW
Huntsville, AL, 35805
Phone (256) 705-4224
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.3M
303,722 services
Medicare patients, 2024
1,092
Average age 75
Drug cost, 2024
$7.0M
3,041 prescriptions
Company payments, 2025
$2,117
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marshall T Schreeder was code J9271 (injection, pembrolizumab, 1 mg), 24,400 times for 31 patients. In total Marshall T Schreeder billed 303,722 services in 217 codes, and Medicare paid $6.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 24,400 | 31 | $44.71 | $1.1M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 16,120 | 18 | $2.30 | $37K |
| J9299 Injection, nivolumab, 1 mg | Office | 15,080 | 15 | $24.58 | $371K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 14,580 | 16 | $39.07 | $570K |
| J0897 Injection, denosumab, 1 mg | Office | 12,720 | 76 | $19.79 | $252K |
| J0185 Injection, aprepitant, 1 mg | Office | 9,230 | 24 | $1.35 | $12K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 4,440 | 27 | $37.05 | $165K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,286 | 105 | $0.09 | $388 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,000 | 22 | $15.77 | $47K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,510 | 13 | $31.52 | $79K |
| 85025 Blood Count | Office | 2,304 | 890 | $7.57 | $17K |
| 80053 Clinical Chemistry | Office | 2,153 | 881 | $10.27 | $22K |
| 36415 Venipuncture Blood Collection | Office | 2,127 | 880 | $8.63 | $18K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,920 | 47 | $0.25 | $480 |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,130 | 14 | $6.16 | $6,957 |
By year: 2022 $6.8M for 314,512 services; 2023 $6.5M for 317,494 services; 2024 $6.3M for 303,722 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,304 | 890 | $7.57 | $17K |
| 80053 Clinical Chemistry | 2,153 | 881 | $10.27 | $22K |
| 36415 Venipuncture Blood Collection | 2,127 | 880 | $8.63 | $18K |
| 88185 Surgical Pathology Examination | 483 | 22 | $15.92 | $7,688 |
| 83735 Clinical Chemistry | 336 | 164 | $6.52 | $2,190 |
| 83883 Clinical Chemistry | 334 | 103 | $13.16 | $4,394 |
| 84443 Clinical Chemistry | 311 | 127 | $16.46 | $5,119 |
| 84100 Clinical Chemistry | 283 | 118 | $4.65 | $1,316 |
| 82728 Clinical Chemistry | 281 | 228 | $13.04 | $3,665 |
| 83540 Clinical Chemistry | 280 | 228 | $6.23 | $1,743 |
Medicare prescription drug claims, 2024
In 2024, the drug Marshall T Schreeder prescribed most often to Medicare patients was Letrozole, with 162 prescriptions and refills. In total Marshall T Schreeder wrote 3,041 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 162 | 389 | 42 | $3,515 |
| Duloxetine Hcl Generic | 152 | 276 | 44 | $3,333 |
| Eliquis Apixaban | 150 | 196 | 30 | $113K |
| Ondansetron Hcl Generic | 138 | 141 | 67 | $1,796 |
| Dexamethasone Generic | 96 | 105 | 37 | $616 |
| Exemestane Generic | 92 | 182 | 21 | $14K |
| Olanzapine Generic | 91 | 103 | 27 | $481 |
| Tamoxifen Citrate Generic | 84 | 170 | 18 | $2,853 |
| Anastrozole Generic | 76 | 160 | 18 | $1,914 |
| Levothyroxine Sodium Generic | 74 | 123 | 23 | $626 |
| Gabapentin Generic | 67 | 107 | 26 | $475 |
| Oxycodone Hcl Generic | 61 | 61 | 12 | $1,586 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 58 | 58 | 25 | $656 |
| Ibrance Palbociclib | 55 | 55 | Under 11 | $587K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 51 | 51 | 40 | $574 |
Brand drugs: 874 claims; generic drugs: 2,167 claims; opioid claims: 229.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marshall T Schreeder $2,117 ($2,117 in general payments such as food, travel and fees) from 32 companies. The largest payer was Pfizer Inc. with $198.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 6 | $198 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $195 |
| Kite Pharma, Inc. GILD | 2 | $165 |
| Genmab U.S., Inc. GMAB | 2 | $158 |
| Genzyme Corporation SNY | 2 | $157 |
| Secura Bio, Inc. | 1 | $153 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $145 |
| Adc Therapeutics America, Inc. | 2 | $138 |
| Incyte Corporation INCY | 8 | $136 |
| Merck Sharp & Dohme LLC MRK | 3 | $82.12 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.